Table 1 Characteristics of study cohort at baseline (n = 32)
Characteristic | n (%) unless indicated otherwise |
|---|---|
Age in years, median (range) | 63 (37–86) |
Sex | |
 Male | 23 (72%) |
 Female | 9 (28%) |
BMI, median (range) | 26 (20–38) |
Primary site | |
 Colon | 23 (72%) |
 Rectum | 9 (28%) |
Definitive treatment to primary tumour | 26 (81%) |
Hepatic tumour burdena, median (range) | 9 (1–46) |
Hepatic tumour burdena > 25% | 4 (13%) |
Extrahepatic metastasesb | 23 (72%) |
Location of extrahepatic metastases | Â |
 Lungs alone | 13 |
 Lung and lymph nodes | 2 |
 Lymph nodes alone | 5 |
 Other | 3 |
Prior therapies | |
 Lines of chemotherapy  1 | 9 (28%) |
 2 | 22 (69%) |
 Anti-VEGF/EGFR mAb | 28 (88%) |
 Hepatic resection | 11 (34%) |
 RFA/SBRTc to liver | 2 (6%) |
 Isolated liver oxaliplatin | 1 (3%) |
 Radiotherapy to extrahepatic sites | 6 (19%) |
RAS mutation statusd | |
 Wild type | 14 (44%) |
 Mutant | 10 (31%) |
 Unknown | 8 (25%) |
Treatment to both liver lobes | 19 (59%) |
Prescribed amount of 90Y for treatment in GBq, median (range)e | 1.68 (0.42–2.08) |
Time to follow-up FDG PET/CTe in days, median (range) | 56 (38–80) |